CO 002: HUMAN ANTIBODIES REACTIVE TO NEUGCGM3 GANGLIOSIDE HAVE CYTOTOXIC ANTITUMOR PROPERTIES

Excerpt:


J Pharm Pharmacogn Res 2(Suppl. 1): S2, 2014 Special supplement with the abstract book of LATINFARMA 2013 Oral Communication CO 002: HUMAN ANTIBODIES REACTIVE TO NEUGCGM3 GANGLIOSIDE HAVE CYTOTOXIC ANTITUMOR PROPERTIES Rodríguez-Zhurbenko N, Martínez D, Blanco R, Rondón T, Griñán T, Hernández AM. Center of Molecular Immunology, Havana, Cuba. E-mail: nely@cim.sld.cu Abstract Introduction: NeuGcGM3 ganglioside is … Continue reading CO 002: HUMAN ANTIBODIES REACTIVE TO NEUGCGM3 GANGLIOSIDE HAVE CYTOTOXIC ANTITUMOR PROPERTIES

J Pharm Pharmacogn Res 2(Suppl. 1): S2, 2014

Special supplement with the abstract book of LATINFARMA 2013

Oral Communication

CO 002: HUMAN ANTIBODIES REACTIVE TO NEUGCGM3 GANGLIOSIDE HAVE CYTOTOXIC ANTITUMOR PROPERTIES

Rodríguez-Zhurbenko N, Martínez D, Blanco R, Rondón T, Griñán T, Hernández AM.

Center of Molecular Immunology, Havana, Cuba. E-mail: nely@cim.sld.cu
Abstract

Introduction: NeuGcGM3 ganglioside is not naturally expressed in normal human tissues but is overexpressed in several tumors and has immunosuppressive capacity, contributing to cancer progression. These features make NeuGcGM3 an attractive candidate for tumor immunotherapy; however, little is known about the naturally occurring anti-NeuGcGM3 antibody response in healthy humans.

Aims of this study were to analyze and characterize the antibody responses against this ganglioside in healthy donors and cancer patients.

Material and methods: The study comprised 100 healthy donors and 55 age-matched untreated non small cell lung cancer (NSCLC) patients. In all the subjects, specific anti-NeuGcGM3 antibody response was assessed by ELISA. The functionality of these antibodies was tested as their ability to bind and kill tumor cell lines expressing NeuGcGM3.

Results: 65 healthy donors had antibodies that specifically recognized NeuGcGM3 and kill tumor cells expressing this antigen by a complement mediated mechanism. Interestingly, even after complement inactivation, 17% of the positive sera showed a direct cytotoxic effect on the tumor cells. This cytotoxicity was dependent on the presence of the antigen on the tumor cells and resembles an oncotic kind of cell death. Both, the levels of anti-NeuGcGM3 antibodies in the sera of healthy donors as well as the percentage of donors with this natural immunity decrease with age. Furthermore, we could only detect low reactivity against NeuGcGM3 in the sera of 6 NSCLC patients.

Conclusions: Healthy human sera contain naturally occurring antiNeuGcGM3 antibodies with cytotoxic anti-tumor properties, reinforcing the importance of NeuGcGM3 ganglioside as an important target for cancer immunotherapy. Treatments that boosted this antiNeuGcGM3 antibody response should be considered an important immunotherapeutic regimen against NeuGcGM3 containing tumors as elderly donors and NSCLC patients lacked this natural anti-tumor response.

Phyllanthus emblica flavonoid glycosides against xanthine oxidase
J. Pharm. Pharmacogn. Res., vol. 12, no. 6, pp. 1067-1078, Nov-Dec 2024. DOI: https://doi.org/10.56499/jppres24.1959_12.6.1067 Original Article Antioxidant potential and xanthine oxidase inhibition of flavonol glycosides from Phyllanthus emblica L. leaves [Potencial antioxidante e inhibición de la xantina oxidasa de los glucósidos de flavonol de las hojas de Phyllanthus emblica L.] Husnunnisa1, Rika Hartati1, Rachmat Mauludin2, … Continue reading Phyllanthus emblica flavonoid glycosides against xanthine oxidase
Spray-drying Perilla frutescens extract optimization
J. Pharm. Pharmacogn. Res., vol. 12, no. 6, pp. 1056-1066, Nov-Dec 2024. DOI: https://doi.org/10.56499/jppres24.2009_12.6.1056 Original Article Optimization of spray-drying conditions and quality assessment of dry extract from Perilla frutescens (L.) Britton leaves [Optimización de las condiciones de secado por atomización y evaluación de la calidad del extracto seco de hojas de Perilla frutescens (L.) Britton] … Continue reading Spray-drying Perilla frutescens extract optimization
Honey clinical applications in complementary medicine
J. Pharm. Pharmacogn. Res., vol. 12, no. 6, pp. 1040-1055, Nov-Dec 2024. DOI: https://doi.org/10.56499/jppres24.1870_12.6.1040 Review Honey clinical applications in complementary medicine: A critical review [Aplicaciones clínicas de la miel en la medicina complementaria: Una revisión crítica] Thai Hau Koo1, Andee Dzulkarnaen Zakaria2*, Mohd Zulkifli Mustafa3 1Department of Internal Medicine, School of Medical Sciences, Universiti Sains … Continue reading Honey clinical applications in complementary medicine

© 2013-2020 by the authors; licensee JPPRes, Antofagasta, Chile. This journal is an open-access journal distributed under the terms and conditions of the Creative Commons Attribution license-Non Commercial 4.0 international. The content on this site is intended for health professionals. If you are not a health professional, please talk to your doctor about any doubts or concerns regarding your health

Made with ♥ by AVAGAX Studio